CD22 and precursor B-cell acute lymphoblastic leukemia: In addition to epigenetic modulators and GSI, another small molecule drug, protein kinase C inhibitor bryostatin I, can stabilize CD22 in B-ALL and B-NHL and improve CD22 CAR T cell functionality and durability of response (29).